CA2938126A1 - Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators - Google Patents
Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators Download PDFInfo
- Publication number
- CA2938126A1 CA2938126A1 CA2938126A CA2938126A CA2938126A1 CA 2938126 A1 CA2938126 A1 CA 2938126A1 CA 2938126 A CA2938126 A CA 2938126A CA 2938126 A CA2938126 A CA 2938126A CA 2938126 A1 CA2938126 A1 CA 2938126A1
- Authority
- CA
- Canada
- Prior art keywords
- tbk1
- nervous system
- sympathetic nervous
- subject
- ikk8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2014/015387 WO2015119624A1 (en) | 2014-02-07 | 2014-02-07 | COMBINATIONS OF IKKε/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2938126A1 true CA2938126A1 (en) | 2015-08-13 |
Family
ID=53778306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2938126A Abandoned CA2938126A1 (en) | 2014-02-07 | 2014-02-07 | Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3102206A4 (de) |
JP (1) | JP2017507930A (de) |
CN (1) | CN106132413A (de) |
AU (1) | AU2014381711A1 (de) |
CA (1) | CA2938126A1 (de) |
WO (1) | WO2015119624A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2659763T3 (es) | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
EP2991647B1 (de) | 2013-05-02 | 2019-04-24 | The Regents Of The University Of Michigan | Deuteriertes amlexanox mit verbesserter metabolischer stabilität |
US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
JP7152051B2 (ja) * | 2018-05-29 | 2022-10-12 | 株式会社ナノエッグ | アトピー性皮膚炎を治療または予防するための組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525359A (en) * | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
EP2437741A1 (de) * | 2009-06-01 | 2012-04-11 | Biocopea Limited | Verwendung von amlexanox bei der behandlung von neutrophilen-gesteuerten erkrankungen |
CA2806825C (en) * | 2010-08-05 | 2018-08-21 | Institut Pasteur De Lille | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
ES2659763T3 (es) * | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
-
2014
- 2014-02-07 CA CA2938126A patent/CA2938126A1/en not_active Abandoned
- 2014-02-07 AU AU2014381711A patent/AU2014381711A1/en not_active Abandoned
- 2014-02-07 JP JP2016550219A patent/JP2017507930A/ja active Pending
- 2014-02-07 WO PCT/US2014/015387 patent/WO2015119624A1/en active Application Filing
- 2014-02-07 EP EP14881460.1A patent/EP3102206A4/de not_active Withdrawn
- 2014-02-07 CN CN201480077641.5A patent/CN106132413A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2017507930A (ja) | 2017-03-23 |
EP3102206A4 (de) | 2017-09-20 |
EP3102206A1 (de) | 2016-12-14 |
WO2015119624A1 (en) | 2015-08-13 |
CN106132413A (zh) | 2016-11-16 |
AU2014381711A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Agard et al. | Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension | |
Mowers et al. | Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1 | |
Combs et al. | Adiponectin signaling in the liver | |
Zou et al. | Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4 | |
Edmonds et al. | Development of small-molecule inhibitors of sphingosine-1-phosphate signaling | |
Silveira et al. | Activating cAMP/PKA signaling in skeletal muscle suppresses the ubiquitin-proteasome-dependent proteolysis: implications for sympathetic regulation | |
Aluja et al. | Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2 | |
US11278549B2 (en) | Method of treating obesity | |
CN101754687A (zh) | 代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗 | |
Fritsche et al. | IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise | |
JP2019116487A (ja) | 脂質動員特性を有する糖タンパク質およびその治療的使用法 | |
CA2938126A1 (en) | Combinations of ikke/tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators | |
Muller et al. | Overactivation of the endocannabinoid system alters the antilipolytic action of insulin in mouse adipose tissue | |
WO2019223688A1 (zh) | 化合物fg-4592在制备治疗甲状腺激素受体介导疾病及药物制剂中的应用 | |
US20150366865A1 (en) | A method of treating obesity | |
US20150224089A1 (en) | COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS | |
US20200331828A1 (en) | Novel compounds which activate estrogen receptors and compositions and methods of using the same | |
AU2007330607B2 (en) | Treatment of cachexia | |
JP2010518860A (ja) | Lynキナーゼの活性化剤の同定方法 | |
Haddish et al. | L-dihydroxyphenylalanine (L-Dopa) induces brown-like phenotype in 3T3-L1 white adipocytes via activation of dopaminergic and β3-adrenergic receptors | |
EP3361250B1 (de) | Midodrine zur induktion von übungsähnlichen effekten | |
CN109550051B (zh) | 组蛋白去甲基化酶kdm6a抑制剂在制备肥胖症治疗药物的用途 | |
US9370504B2 (en) | Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α | |
WO2017165908A1 (en) | Method of inhibiting high fat diet-related conditions | |
Yu et al. | Atractylodin alleviates cancer anorexia-cachexia syndrome by regulating NPY through hypothalamic Sirt1/AMPK axis-induced autophagy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20200207 |